SignaBlok's therapeutic programs are driven by one aim and singular focus – to help patients with serious diseases with unmet clinical needs and improve their lives. Most of these diseases are linked to inflammation. That is why SignaBlok has targeted the TREM-1 receptor, a unique switch between protective and detrimental inflammation.
Considering a critical role of inflammation in a vast majority of seemingly unrelated diseases and conditions, pharmacological interventions targeting TREM-1 and TREM-2 pathways have been often hailed as the prototypical magic bullet drugs. This makes collaborations and partnerships especially crucial on this road to success.